Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.51 |
| ▸ | RAB9A | P51151 | 9/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.43 |
| ▸ | RELA | Q04206 | 4/20 | 0.43 |
| ▸ | CASP3 | P42574 | 3/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1678137 | 0.85 | RAB9A (0.53) | NPC1RAB9AKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1678929 | 0.83 | QPCT (0.60) | NPC1RAB9AKDM4EKMT2ANFKB1 | |
| SCHEMBL14395070 | 0.83 | RAB9A (0.48) | NPC1RAB9AKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1677802 | 0.83 | HSD17B10 (0.50) | NPC1RAB9AKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1678651 | 0.82 | NOS3 (0.55) | NPC1RAB9AKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1678134 | 0.82 | RAB9A (0.48) | NPC1RAB9AKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1678352 | 0.82 | NOS3 (0.65) | NPC1RAB9AKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1678641 | 0.80 | NOS3 (0.48) | NPC1RAB9AKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL1678623 | 0.80 | NOS3 (0.66) | NPC1RAB9AKDM4EALDH1A1NOS3 | |
| SCHEMBL1677883 | 0.78 | NOS3 (0.62) | NPC1RAB9AKDM4EKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4664673-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| EP-1539724-B1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2007-10-10 | — | — | EP | claimed |
| US-7141595-B2 | Amino benzothiazole compounds with NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-28 | — | — | US | claimed |
| JP-2006501210-A | — | — | 2006-01-12 | — | — | JP | claimed |
| US-20050209291-A1 | N-(2-Amino-benzothiazol-6-yl)-ethylthiocarboximidamide or other amino benzothiazole derivatives as neuroprotectants and for the treatment of neuropathic pain | NEURAXON INC. (CA) | 2005-09-22 | — | — | US | claimed |
| EP-1539724-A1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2005-06-15 | — | — | EP | claimed |
| WO-2004014885-A1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2004-02-19 | — | — | WO | claimed |
| EP-1539724-B1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2007-10-10 | — | — | EP | disclosed |
| US-7141595-B2 | Amino benzothiazole compounds with NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-28 | — | — | US | disclosed |
| US-20050209291-A1 | N-(2-Amino-benzothiazol-6-yl)-ethylthiocarboximidamide or other amino benzothiazole derivatives as neuroprotectants and for the treatment of neuropathic pain | NEURAXON INC. (CA) | 2005-09-22 | — | — | US | disclosed |
| EP-1539724-A1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014885-A1 | AMINO BENZOTHIAZOLE COMPOUNDS WITH NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209291-A1 | N-(2-Amino-benzothiazol-6-yl)-ethylthiocarboximidamide or other amino benzothiazole derivatives as neuroprotectants and for the treatment of neuropathic pain | GAP43, NLN, TRPV1 | NPC1 689/4885RAB9A 4490/4885KDM4E 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.